 |
PDBsum entry 1qr9
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
1qr9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Virol
73:8578-8586
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.
|
|
H.Ji,
W.Shu,
F.T.Burling,
S.Jiang,
M.Lu.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The gp41 envelope protein of human immunodeficiency virus type 1 (HIV-1)
contains an alpha-helical core structure responsible for mediating membrane
fusion during viral entry. Recent studies suggest that a conserved hydrophobic
cavity in the coiled coil of this core plays a distinctive structural role in
maintaining the fusogenic conformation of the gp41 molecule. Here we
investigated the importance of this cavity in determining the structure and
biological activity of the gp41 core by using the N34(L6)C28 model. The
high-resolution crystal structures of N34(L6)C28 of two HIV-1 gp41
fusion-defective mutants reveal that each mutant sequence is accommodated in the
six-helix bundle structure by forming the cavity with different sets of atoms.
Remarkably, the mutant N34(L6)C28 cores are highly effective inhibitors of HIV-1
infection, with 5- to 16-fold greater activity than the wild-type molecule. The
enhanced inhibitory activity by fusion-defective mutations correlates with local
structural perturbations close to the cavity that destabilize the six-helix
bundle. Taken together, these results indicate that the conserved hydrophobic
coiled-coil cavity in the gp41 core is critical for HIV-1 entry and its
inhibition and provides a potential antiviral drug target.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Ashkenazi,
and
Y.Shai
(2011).
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.
|
| |
Eur Biophys J,
40,
349-357.
|
 |
|
|
|
|
 |
M.I.Qadir,
and
S.A.Malik
(2010).
HIV fusion inhibitors.
|
| |
Rev Med Virol,
20,
23-33.
|
 |
|
|
|
|
 |
M.P.Chien,
C.H.Lin,
and
D.K.Chang
(2009).
Recruitment of HIV-1 envelope occurs subsequent to lipid mixing: a fluorescence microscopic evidence.
|
| |
Retrovirology,
6,
20.
|
 |
|
|
|
|
 |
T.Naito,
K.Izumi,
E.Kodama,
Y.Sakagami,
K.Kajiwara,
H.Nishikawa,
K.Watanabe,
S.G.Sarafianos,
S.Oishi,
N.Fujii,
and
M.Matsuoka
(2009).
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
|
| |
Antimicrob Agents Chemother,
53,
1013-1018.
|
 |
|
|
|
|
 |
Y.He,
S.Liu,
J.Li,
H.Lu,
Z.Qi,
Z.Liu,
A.K.Debnath,
and
S.Jiang
(2008).
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.
|
| |
J Virol,
82,
11129-11139.
|
 |
|
|
|
|
 |
Z.Qi,
W.Shi,
N.Xue,
C.Pan,
W.Jing,
K.Liu,
and
S.Jiang
(2008).
Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.
|
| |
J Biol Chem,
283,
30376-30384.
|
 |
|
|
|
|
 |
B.Strockbine,
and
R.C.Rizzo
(2007).
Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment.
|
| |
Proteins,
67,
630-642.
|
 |
|
|
|
|
 |
L.E.Luque,
and
C.J.Russell
(2007).
Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.
|
| |
J Virol,
81,
3130-3141.
|
 |
|
|
|
|
 |
R.Chinnadurai,
D.Rajan,
J.Münch,
and
F.Kirchhoff
(2007).
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.
|
| |
J Virol,
81,
6563-6572.
|
 |
|
|
|
|
 |
D.Delcroix-Genête,
P.L.Quan,
M.G.Roger,
U.Hazan,
S.Nisole,
and
C.Rousseau
(2006).
Antiviral properties of two trimeric recombinant gp41 proteins.
|
| |
Retrovirology,
3,
16.
|
 |
|
|
|
|
 |
W.M.Kazmierski,
T.P.Kenakin,
and
K.S.Gudmundsson
(2006).
Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
|
| |
Chem Biol Drug Des,
67,
13-26.
|
 |
|
|
|
|
 |
Y.Xu,
H.Lu,
J.P.Kennedy,
X.Yan,
L.A.McAllister,
N.Yamamoto,
J.A.Moss,
G.E.Boldt,
S.Jiang,
and
K.D.Janda
(2006).
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation.
|
| |
J Comb Chem,
8,
531-539.
|
 |
|
|
|
|
 |
W.Ou,
and
J.Silver
(2005).
Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera.
|
| |
Retrovirology,
2,
51.
|
 |
|
|
|
|
 |
T.Krell,
F.Greco,
O.Engel,
J.Dubayle,
J.Dubayle,
A.Kennel,
B.Charloteaux,
R.Brasseur,
M.Chevalier,
R.Sodoyer,
and
R.El Habib
(2004).
HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants.
|
| |
Eur J Biochem,
271,
1566-1579.
|
 |
|
|
|
|
 |
T.Murakami,
S.Ablan,
E.O.Freed,
and
Y.Tanaka
(2004).
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
|
| |
J Virol,
78,
1026-1031.
|
 |
|
|
|
|
 |
R.M.Markosyan,
F.S.Cohen,
and
G.B.Melikyan
(2003).
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.
|
| |
Mol Biol Cell,
14,
926-938.
|
 |
|
|
|
|
 |
S.Giannecchini,
A.Di Fenza,
A.M.D'Ursi,
D.Matteucci,
P.Rovero,
and
M.Bendinelli
(2003).
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.
|
| |
J Virol,
77,
3724-3733.
|
 |
|
|
|
|
 |
K.E.Follis,
S.J.Larson,
M.Lu,
and
J.H.Nunberg
(2002).
Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.
|
| |
J Virol,
76,
7356-7362.
|
 |
|
|
|
|
 |
N.Boutonnet,
W.Janssens,
C.Boutton,
J.L.Verschelde,
L.Heyndrickx,
E.Beirnaert,
G.van der Groen,
and
I.Lasters
(2002).
Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human imunodeficiency virus type 1 gp41 with patient data.
|
| |
J Virol,
76,
7595-7606.
|
 |
|
|
|
|
 |
X.Siebert,
and
G.Hummer
(2002).
Hydrophobicity maps of the N-peptide coiled coil of HIV-1 gp41.
|
| |
Biochemistry,
41,
2956-2961.
|
 |
|
|
|
|
 |
J.Liu,
W.Shu,
M.B.Fagan,
J.H.Nunberg,
and
M.Lu
(2001).
Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion.
|
| |
Biochemistry,
40,
2797-2807.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Lu,
M.O.Stoller,
S.Wang,
J.Liu,
M.B.Fagan,
and
J.H.Nunberg
(2001).
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.
|
| |
J Virol,
75,
11146-11156.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Triantafilou,
K.M.Wilson,
and
K.Triantafilou
(2001).
Identification of Echovirus 1 and coxsackievirus A9 receptor molecules via a novel flow cytometric quantification method.
|
| |
Cytometry,
43,
279-289.
|
 |
|
|
|
|
 |
P.W.Mobley,
R.Pilpa,
C.Brown,
A.J.Waring,
and
L.M.Gordon
(2001).
Membrane-perturbing domains of HIV type 1 glycoprotein 41.
|
| |
AIDS Res Hum Retroviruses,
17,
311-327.
|
 |
|
|
|
|
 |
H.Ji,
C.Bracken,
and
M.Lu
(2000).
Buried polar interactions and conformational stability in the simian immunodeficiency virus (SIV) gp41 core.
|
| |
Biochemistry,
39,
676-685.
|
 |
|
|
|
|
 |
W.Shu,
J.Liu,
H.Ji,
L.Radigen,
S.Jiang,
and
M.Lu
(2000).
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides.
|
| |
Biochemistry,
39,
1634-1642.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |